Table 1. Clinico-pathological data of gynecological cancer cohort sorted by blood group.
| ABO blood group | |||||||
|---|---|---|---|---|---|---|---|
| ALL | O | A | AB | B | p | n | |
| Characteristic | |||||||
| Number of women | 974 | 375 | 471 | 34 | 94 | ||
| Percentage of total (%) | 100.0 | 38.5 | 48.4 | 3.5 | 9.7 | ||
| Cancer Center | 0.038 | 974 | |||||
| Basel | 708 (72.7%) | 265 (70.7%) | 364 (77.3%) | 22 (64.7%) | 57 (60.6%) | ||
| Sydney | 210 (21.6%) | 89 (23.7%) | 83 (17.6%) | 9 (26.5%) | 29 (30.9%) | ||
| Zürich | 56 (5.75%) | 21 (5.60%) | 24 (5.10%) | 3 (8.82%) | 8 (8.51%) | ||
| Mean age (years) (±SD) | 62.8 (13.7) | 63.1 (13.8) | 62.9 (13.5) | 62.3 (12.2) | 61.5 (14.5) | 0.786 | 940 |
| Organ | 0.035 | 974 | |||||
| Cervix | 149 (15.3%) | 54 (14.4%) | 81 (17.2%) | 5 (14.7%) | 9 (9.57%) | ||
| Endometrium | 377 (38.7%) | 156 (41.6%) | 182 (38.6%) | 13 (38.2%) | 26 (27.7%) | ||
| Ovaries | 282 (29.0%) | 100 (26.7%) | 138 (29.3%) | 10 (29.4%) | 34 (36.2%) | ||
| Ovaries & Endometrium | 9 (0.92%) | 2 (0.53%) | 5 (1.06%) | 1 (2.94%) | 1 (1.06%) | ||
| Peritoneum | 56 (5.75%) | 22 (5.87%) | 18 (3.82%) | 3 (8.82%) | 13 (13.8%) | ||
| Fallopian tube | 23 (2.36%) | 9 (2.40%) | 9 (1.91%) | 1 (2.94%) | 4 (4.26%) | ||
| Vagina | 11 (1.13%) | 8 (2.13%) | 3 (0.64%) | 0 (0.00%) | 0 (0.00%) | ||
| Vulva | 67 (6.88%) | 24 (6.40%) | 35 (7.43%) | 1 (2.94%) | 7 (7.45%) | ||
| Tumour type | 0.183 | 974 | |||||
| Adenocarcinoma | 733 (75.3%) | 286 (76.3%) | 345 (73.2%) | 25 (73.5%) | 77 (81.9%) | ||
| Squamous cell carcinoma | 193 (19.8%) | 71 (18.9%) | 103 (21.9%) | 6 (17.6%) | 13 (13.8%) | ||
| Carcinosarcoma (MMMT) | 26 (2.67%) | 11 (2.93%) | 12 (2.55%) | 1 (2.94%) | 2 (2.13%) | ||
| Adenosarcoma | 1 (0.10%) | 1 (0.27%) | 0 (0.00%) | 0 (0.00%) | 0 (0.00%) | ||
| Adenosquamous carcinoma | 2 (0.21%) | 1 (0.27%) | 1 (0.21%) | 0 (0.00%) | 0 (0.00%) | ||
| Sarcoma | 7 (0.72%) | 4 (1.07%) | 0 (0.00%) | 2 (5.88%) | 1 (1.06%) | ||
| Carcinoid | 1 (0.10%) | 1 (0.27%) | 0 (0.00%) | 0 (0.00%) | 0 (0.00%) | ||
| Brenner tumor | 3 (0.31%) | 0 (0.00%) | 2 (0.42%) | 0 (0.00%) | 1 (1.06%) | ||
| Sertoli-Leydig tumor | 2 (0.21%) | 0 (0.00%) | 2 (0.42%) | 0 (0.00%) | 0 (0.00%) | ||
| Granulosacell tumor | 6 (0.62%) | 0 (0.00%) | 6 (1.27%) | 0 (0.00%) | 0 (0.00%) | ||
| Histology | 0.427 | 709 | |||||
| Serous | 251 (35.4%) | 92 (33.3%) | 115 (34.3%) | 9 (37.5%) | 35 (47.3%) | ||
| Endometrioid | 339 (47.8%) | 132 (47.8%) | 165 (49.3%) | 11 (45.8%) | 31 (41.9%) | ||
| Mucinous | 24 (3.39%) | 9 (3.26%) | 10 (2.99%) | 1 (4.17%) | 4 (5.41%) | ||
| Clear cell | 23 (3.24%) | 9 (3.26%) | 12 (3.58%) | 2 (8.33%) | 0 (0.00%) | ||
| Neuroendocrine | 3 (0.42%) | 1 (0.36%) | 1 (0.30%) | 0 (0.00%) | 1 (1.35%) | ||
| Mixed/unknown/other | 69 (9.73%) | 33 (4.65%) | 32 (4.51%) | 1 (0.14%) | 3 (0.42%) | ||
| FIGO Stage | 0.524 | 662 | |||||
| I | 259 (39.1%) | 105 (40.5%) | 111 (36.2%) | 11 (45.8%) | 32 (44.4%) | ||
| II | 85 (12.8%) | 31 (12.0%) | 45 (14.7%) | 4 (16.7%) | 5 (6.94%) | ||
| III | 242 (36.6%) | 95 (36.7%) | 110 (35.8%) | 7 (29.2%) | 30 (41.7%) | ||
| IV | 76 (11.5%) | 28 (10.8%) | 41 (13.4%) | 2 (8.33%) | 5 (6.94%) | ||
| Tumour grade | 0.510 | 762 | |||||
| G1 | 185 (24.3%) | 66 (22.2%) | 96 (26.2%) | 3 (12.5%) | 20 (26.7%) | ||
| G2 | 238 (31.2%) | 98 (33.0%) | 112 (30.6%) | 6 (25.0%) | 22 (29.3%) | ||
| G3 | 339 (44.5%) | 133 (44.8%) | 158 (43.2%) | 15 (62.5%) | 33 (44.0%) | ||
| Residual Disease | 0.571 | 441 | |||||
| optimal debulking | 303 (68.7%) | 118 (67.4%) | 144 (70.9%) | 10 (76.9%) | 31 (62.0%) | ||
| suboptimal debulking | 138 (31.3%) | 57 (32.6%) | 59 (29.1%) | 3 (23.1%) | 19 (38.0%) | ||
| Survival status | 0.962 | 933 | |||||
| alive | 829 (88.9%) | 317 (89.0%) | 401 (88.5%) | 29 (87.9%) | 82 (90.1%) | ||
| dead of disease | 104 (11.1%) | 39 (11.0%) | 52 (11.5%) | 4 (12.1%) | 9 (9.89%) | ||
| Recurrence | 0.009 | 974 | |||||
| no | 750 (77.0%) | 298 (79.5%) | 368 (78.1%) | 24 (70.6%) | 60 (63.8%) | ||
| yes | 108 (23.0%) | 77 (20.5%) | 103 (21.9%) | 10 (29.4%) | 34 (36.2%) | ||
Data from gynecological cancer centers (Basel and Zurich, Switzerland) and Sydney (Australia) collected between 1974 and 2014. P-values calculated by t-test or Fisher’s exact tests.